Compare · MDLN vs TELA
MDLN vs TELA
Side-by-side comparison of Medline Inc. (MDLN) and TELA Bio Inc. (TELA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and TELA operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $47.24B, about 955.6x TELA ($49.4M).
- Over the past year, MDLN is down 10.6% and TELA is down 35.0% - MDLN leads by 24.4 points.
- MDLN has been more active in the news (7 items in the past 4 weeks vs 6 for TELA).
- MDLN has more recent analyst coverage (25 ratings vs 3 for TELA).
- Company
- Medline Inc.
- TELA Bio Inc.
- Price
- $36.41-0.48%
- $0.97-4.58%
- Market cap
- $47.24B
- $49.4M
- 1M return
- +13.42%
- -23.13%
- 1Y return
- -10.63%
- -35.00%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2019
- News (4w)
- 7
- 6
- Recent ratings
- 25
- 3
TELA Bio Inc.
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest TELA
- SEC Form 8-K filed by TELA Bio Inc.
- SEC Form 8-K filed by TELA Bio Inc.
- TELA Bio Inc. filed SEC Form 8-K: Other Events
- TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
- TELA Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Craig Hallum initiated coverage on TELA Bio with a new price target
- Director Capper Joseph H bought $88,795 worth of shares (75,000 units at $1.18), increasing direct ownership by 72% to 179,827 units (SEC Form 4)
- TELA Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Director Capper Joseph H bought $78,442 worth of shares (75,000 units at $1.05), increasing direct ownership by 251% to 104,827 units (SEC Form 4)
- SEC Form DEF 14A filed by TELA Bio Inc.